Clinical trials: B-Cell ALL
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safe Accelerated Venetoclax Escalation in CLL
This research study is trying to determine which patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), as grouped by their risk for tumor lysis syndrome…
- Trial name
- SAVE (NCT04843904)
- Testing
- Venetoclax, Obinutuzumab, Rituximab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphoid Leukemia
Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax
Chronic lymphocytic leukemia is a malignant blood disorder characterized by the proliferation of abnormal B lymphocytes in the blood, lymph nodes, and bone marrow.
- Trial name
- ELYSA (NCT07691047)
- Testing
- Cervical, Thoracic, Abdominal, and Pelvic CT Scan
- Where
- 2 sites in France
- Volunteers
- 130 people
- Sponsor
- Private Hospital of Confluent, France
Leukemia, Lymphocytic, Chronic, B-Cell
DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia
Phase 2 study to assess the efficacy of INVAC-1, a DNA plasmid encoding a modified human telomerase reverse transcriptas (hTERT) protein, at a dose of 800 µg for 6 cycles 4 weeks apart on Minimal Residual Disease (MRD)…
- Trial name
- NCT03265717
- Testing
- INVAC-1
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Invectys
B-cell Non-Hodgkin's Lymphoma (B-NHL)
Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
The main objective of this study is to observe and evaluate the safety and tolerability of the XP-006 personalized tumor mRNA vaccine for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
- Trial name
- XP-006 (NCT07334574)
- Testing
- Personalized neoantigen tumor vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Lymphoma
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00290706
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Meningococcal Infections
Regulation of Mucosal Immune Response to Systemic MenB Vaccine
Meningitis or septicaemia (blood poisoning) caused by group B meningococcal infection (MenB) is an important cause of death and disability in the UK. Prevention through vaccination therefore remains a key public health priority.
- Trial name
- NCT00774384
- Testing
- NZ MenB OMV vaccine (NZ98/254)
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Chronic Lymphocytic Leukemia
An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia
This study will examine the effectiveness of MabThera therapy added to a standard chemotherapy regimen for the treatment of previously untreated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02080884
- Where
- 15 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
B-Cell Non-Hodgkin Lymphoma
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- NCT05201248
- Testing
- Epcoritamab, Cyclophosphamide, Rituximab
- Where
- 18 sites in China
- Volunteers
- 49 people
- Sponsor
- Genmab
HIV-1 Infection
Lipopeptide Immunisation With GTU-multiHIV Trial
The combination of GTU-MultiHIV B DNA and LIPO-5 vaccines in a prime-boost strategy is expected to induce strong and diverse HIV-specific immune responses in HIV-infected patients.
- Trial name
- NCT01492985
- Testing
- GTU-multHIV B vaccine and LIPO-5 vaccine
- Where
- France
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Lymphocytic Leukemia
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
This is a multicentre single-arm prospective phase II trial evaluating pirtobrutinib in the treatment of relapsed/refractory (R/R) Chronic Lymphocytic Leukaemia (CLL) patients who have previously received zanubrutinib, and to…
- Trial name
- PIPOZA (NCT06812715)
- Testing
- Pirtobrutinib
- Where
- 3 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
DLBCL
CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)
This was an open, multicenter clinical study of newly treated DLBCL patients with TP53 mutations and del(17p) with IPI>1. Participants who met the inclusion/exclusion criteria signed informed consent and received 1 course of…
- Trial name
- NCT06750991
- Testing
- CDR-CHOP
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Ruijin Hospital
Central Nervous System B-Cell Non-Hodgkin Lymphoma, Recurrent Central Nervous System Lymphoma
Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
This phase II trial studies the side effects and how well nivolumab and ibrutinib works in treating patients with central nervous system lymphoma that has come back or does not respond to treatment.
- Conditions
- Central Nervous System B-Cell Non-Hodgkin Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
- Trial name
- NCT03770416
- Testing
- Ibrutinib, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lymphoma, Large B-Cell, Diffuse
Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression
DLBCL has the highest frequency out of all lymphoid malignancies. With the recent development of antitumor agents targeting intracellular/extracellular cell signaling pathways, patients have access to various treatment options…
- Trial name
- COGET-B (NCT03977623)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Relapsed and/or Refractory Acute Lymphoblastic Leukemia, Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma
CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
A study of CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
- Trial name
- NCT04609241
- Testing
- CD79b CAR-T Cells
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Zhejiang University
Leukemia
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
The goal of the clinical research study is to find the highest tolerable dose of nelarabine when given as a continuous infusion to patients with a lymphoid malignancy that has not responded to, or has come back after treatment…
- Trial name
- NCT01094860
- Testing
- Nelarabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
This is an open label, phase II study to evaluate the capacity of Rituximab (Mabthera®) plus Lenalidomide (Revlimid®) to induce objective responses in patients with Mucosa Associated Lymphoid Tissue (MALT) lymphoma presenting…
- Trial name
- NCT01611259
- Testing
- Rituximab and Lenalidomide
- Where
- 5 sites in Austria
- Volunteers
- 50 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
B-cell Malignancy
Phase I Study of HRS-3005 in B-cell Malignancies
The study is being conducted to evaluate the safety and tolerability of HRS-3005. To explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D).
- Trial name
- NCT07556822
- Testing
- HRS-3005
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
B-cell Tumors
A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects
This study used a single-dose, open and fixed sequence design to compare the pharmacokinetics in healthy subjects.
- Trial name
- NCT05560360
- Testing
- SHR1459 tablet, Efavirenz tablet
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chronic Hepatitis B, Alcoholic Hepatitis
Alcohol Consumption and Plasma cfDNA Methylation in Chronic Hepatitis B
This is an observational, exploratory study designed to investigate the effect of different levels of alcohol consumption on plasma cell-free DNA (cfDNA) methylation profiles in participants with chronic hepatitis B.
- Trial name
- NCT07865520
- Testing
- Alcohol Consumption
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Beijing Municipal Administration of Hospitals